: iStockAnalyst.com Symbols Feed

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Sat, 28 Nov 2009 15:59:46 GMT

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular[More...]

Diabetes Care: Global Investing Opportunities

Mon, 23 Nov 2009 03:23:59 GMT

The American Diabetes Association estimates that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billion in costs from diagnosed cases of diabetes in the U.S. (2007).[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Market Closing: Stocks, Oil, Gold Rally On Improved Optimism After Australia Raises Rates

Tue, 06 Oct 2009 20:55:00 GMT

Stocks and commodities gained after the Bank of Australia became the first Group of 20 central bank to raise interest rates and ahead of a fresh round of earnings reports that bulls are betting will show better revenues confirm an improving corporate climate.[More...]

Options Activity In Biotech Bets

Mon, 21 Sep 2009 14:36:00 GMT

"Two biotechs in our portfolio have seen an unusual amount of option activity in recent weeks/months," notes 20-year sector veteran Nate Pile. Here's the latest in Nate's Notes.[More...]

MannKind (Nasdaq: MNKD): High Risk Bet On Inhaled Insulin

Wed, 01 Jul 2009 16:42:01 GMT

"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile. In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose[More...]

Biotechnology Industry - Zacks Analyst Interviews

Fri, 05 Dec 2008 12:44:00 GMT

Historically, the biotech industry was less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by restructuring. Some even have to suspend operations[More...]

Biotechnology Industry

Thu, 04 Dec 2008 20:05:00 GMT

Historically, the biotech industry has been less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. ? However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by[More...]

Earnings Review – Nov 5

Wed, 05 Nov 2008 13:51:00 GMT

Here is a summary of the notable earnings for today’s markets as we welcome the ideologies of a new President elect, hoping the dawn of a new era for the nation as well as the financial markets.[More...]

Earnings Preview For Nov 3 - 7 - Earnings Preview

Sat, 01 Nov 2008 01:58:00 GMT

Companies that could issue positive surprises include Becton, Dickinson and Company (BDX), SucessFactors (SFSF) and Sunoco (SUN). Penn Virginia Corporation (PVA) could potentially disappoint investors. The Week's Events November has historically been one of the best months for the major markets, according to the[More...]

SemBioSys announces third quarter 2009 financial and operational results

Fri, 13 Nov 2009 11:46:00 GMT

CALGARY, Nov. 13 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009 financial and operational results.
"We entered into an agreement with Cathedral Energy Services Income Trust, subsequent to the end of the quarter, which will provide us with gross proceeds of approximately $3.3 million in new non-dilutive capital.
This capital infusion will extend the development runway for our Apo AI(Milano) and Biosimilar Insulin programs," said James Szarko, President and Chief Executive Officer of SemBioSys.

: iStockAnalyst.com Symbols Feed

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Diabetes Care: Global Investing Opportunities

Big Pharma And Biotech - Industry Outlook

Market Closing: Stocks, Oil, Gold Rally On Improved Optimism After Australia Raises Rates

Options Activity In Biotech Bets

MannKind (Nasdaq: MNKD): High Risk Bet On Inhaled Insulin

Biotechnology Industry - Zacks Analyst Interviews

Biotechnology Industry

Earnings Review – Nov 5

Earnings Preview For Nov 3 - 7 - Earnings Preview

SemBioSys announces third quarter 2009 financial and operational results

SemBioSys Announces Second Quarter 2009 Financial and Operational Results

Analyst Picks and Pans: General Mills, VeriSign, MannKind

Riding Out the 'Economic Tsunami"

Mid Day Deals: Schering-Plough -Merck, MannKind - Pfizer, Henry Schein, Hale Capital - Autodesk

MannKind, Pfizer Agree on Frankfurt Insulin Manufacturing Plant

In Pharmaceutical Sector, Local Manufacturers Buck Trend

MannKind Announces Completion of Common Stock Offering

MannKind to Present at the 29th Annual Canaccord Adams Global Growth Conference

MannKind Announces Pricing of Public Offering of Common Stock

MannKind Corporation Reports Second Quarter Financial Results

MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 3, 2009

MannKind Announces Positive New Market Survey Information Regarding AFRESA®

BenchmarkJournal.Com Free Analyst Review for GAP, ATU, PPHM, MNKD, HLIT and COCO

MannKind Closes Acquisition of Insulin Assets from Pfizer

MannKind Unveils Next-Generation Inhalation System

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

Form 4 MANNKIND CORP For: Nov 16 Filed by: Thomson David (10K)

Form 4 MANNKIND CORP For: Nov 16 Filed by: Palumbo Diane (10K)

Form 4 MANNKIND CORP For: Nov 16 Filed by: Edstrom Hakan (10K)

Form 4 Palumbo Diane For: Nov 06 (10K)

Form 4 Thomson David For: Sep 24 (10K)

Form 4 Thomson David For: Sep 17 (10K)

Form 4 Thomson David For: Sep 10 (10K)

Form 4 Thomson David For: Sep 03 (10K)

Form 4/A PFEFFER MATTHEW J For: May 18 (10K)

Form 4 Edstrom Hakan For: Aug 15 (10K)